Department of Radiation Oncology (Shen WB,Cao YK,Zhu SHCH,Li YM,Li SHG),Department of Thoracic Surgery (Wen SHW,Zhu H),Forth Hospital,Hebei Medical University,Shijiazhuang 050011,China;Department of Radiation,First Hospital of Shijiazhaung,Shijiazhuang 050011,China (Gao HM)
AbstractObjective To study the relationship between radiation gastritis (RG) caused by esophageal cancer radical postoperative prophylactic IMRT and the dose of gastric. Methods A total of 49 esophageal cancer patients received postoperative adjuvant radiatherapy after esophagectomy,we analysised the dose-volume histogram of treatment plan and the the occurrence of RG,To analysis those physical indicators may be related to the occurrence of RG. The of ROC curve to analysis the physical index of the occurrence of acute radiation gastritis, Chi square test is compared between groups, Logistic method was used to multivariate analysis. Results The whole group,a total of 19 cases (39%) patients with symptoms of acute RG level 2 or higher. The Results of ROC curve analysis showed that the physical variables associated with the occurrence of RG include stomach Max,stomach Mean,LSTT5-LSTT40 and V5-V50.According to the ROC curve,the cutoff values of the physical parameters of the patients were grouped. The incidence of acute ≥2RG in the group of above boundary value patients significantly higher than below boundary value group,the physical index of the differences between groups were significant (P=0.000-0.022),except V5.The Results of Logistic multivariate analysis showed that LSTT5 and V40 were independent predictor of≥2 RG (P=0.026,0.001). Conclusions According to the Results of this study,We should pay attention to the protection of the stomach in develop a treatment plan for the prevention of postoperative patients with esophageal cancer,dose-volume histogram can well predict the occurrence of RG.Stomach LSTT5 and V40 were independent predictor of≥2 RG.The Results of this study need to be further studied.
Shen Wenbin,Gao Hongmei,Zhu Shuchai et al. The dose study of radiation gastritis caused by esophageal cancer radical postoperative prophylactic irradiation[J]. Chinese Journal of Radiation Oncology, 2016, 25(8): 818-822.
Shen Wenbin,Gao Hongmei,Zhu Shuchai et al. The dose study of radiation gastritis caused by esophageal cancer radical postoperative prophylactic irradiation[J]. Chinese Journal of Radiation Oncology, 2016, 25(8): 818-822.
[1] Xiao ZF,Yang ZY,Liang J,et al. Value of radiotherapy after radical surgery for esophageal carcinoma:a report of 495 patients[J].Ann Thorac Surg,2003,75(2):33l-336.DOI:10.1016/S0003-4975(02)04401-6 [2] Rice TW,Rusch VW,Apperson-Hansen C,et al. Worldwide esophageal cancer collaboration[J].Dis Esophagus,2009,22(1):1-8.DOI:10.1111/j.1442-2050.2008.00901.x [3] Worni M,Martin J,Gloor B,et al. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008[J].J Am Coll Surg,2012,215(5):643-651.DOI:10.1016/j.jamcollsurg.2012.07.006 [4] Chen G,Wang Z,Lu XY,et al. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified lvor-Lewis esophagectomy[J].World J Surg,2007,31(5):1108-1115.DOI:10.1007/s00268-006-0551-1 [5] Smit JK,Pultrum BB,van Dullemen HM,et al. Prognostic factors and patterns of recurrence in esophageal cancer assert arguments for extended two-field transthoracic esophagectomy[J].Am J Surg,2010,200(4):446-453.DOI:10.1016/j.amjsurg.2009.12.006 [6] Li CL,Zhang FL,Wang YD,et al. Characteristics of recurrence after radical esophagectomy with two-field lymph node dissection for thoracic esophageal cancer[J].Oncol Lett,2013,5(1):355-359.DOI:10.3892/ol.2012.946 [7] Chen JQ,Zhu J,Pan JJ,et al. Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus[J].Ann Thorac Surg,2010,90(2):435-442.DOI:10.1016/j.athoracsur.2010.04.002 [8] Schreiber D,Rineer J,Vongtama D,et al. Impact of postoperative radiation after esophagectomy for esophageal cancer[J].J Thorac Oncol,2010,5(2):244-250.DOI:10.1097/JTO.0b013e3181c5e34f [9] Martin JT,Worni M,Zwischenberger JB,et al. The role of radiation therapy in resected T2 No esophageal cancer:a population-based analysis[J].Ann Thorac Surg,2013,95(2):453-458.DOI:10.1016/j.athoracsur.2012.08.049 [10] Xiao ZF,Yang ZY,Miao YJ,et al. Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy:report of 549 cases[J].Int J Radiat Oncol Biol Phys,2005,62(1):82-90.DOI:10.1016/j.ijrobp.2004.08.046 [11] Jin HL,Zhu H,Ling TS,et al. Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma:a meta-analysis[J].World J Gastroenterol,2009,15(47):5983-5991.DOI:10.3748/wjg.15.5983 [12] Yu E,Tai P,Younus J,et al. Postoperative extended-volume external-beam radiation therapy in high-risk esophageal cancer patients:a prospective experience[J].Curr Oncol,2009,16(1):48-54 [13] De Ruysscher D,Van Meerbeeck,Vandecasteele K,et al. Radiation-induced oesophagitis in lung cancer patients:is susceptibility for neutropenia a risk factor?[J].Strahlenther Onkol,2012,188(7):564-567.DOI:10.1007/s00066-012-0098-z [14] Zhang ZC,Xu J,Zhou T,et al. Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy[J].Radiat Oncol,2014,9(2):54-60.DOI:10.1186/1748-717X-9-54 [15] Bar-Ad V,Ohri N,Werner-Wasik M.Esophagitis,treatment-related toxicity in non-small cell lung cancer[J].Rev Recent Clin Trials,2012,7(1):31-35.DOI:10.2174/157488712799363235 [16] Curran Jr WJ,Paulus R,Langer CJ,et al. Sequential vs. concurrent chemoradiation for stage Ⅲ non-small cell lung cancer:randomized phase Ⅲ trial RTOG 9410[J].J Natl Cancer Inst,2011,103(19):1452-1460.DOI:10.1093/jnci/djr325 [17] Bonner JA,Sloan JA,Shanahan TG,et al. Phase Ⅲ comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma[J].J Clin Oncol,1999,17(9):2681-2691 [18] Gazula A,Baldini EH,Chen A,et al. Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer[J].Lung,2014,192(1):151-158.DOI:10.1007/s00408-013-9518-9 [19] Grills IS,Yan D,Martinez AA,et al. Potential for reduced toxicity and dose escalation in the treatment of in operable non-small-cell lung cancer:a comparison of intensity-modulated radiation therapy (IMRT),3D conformal radiation,and elective nodal irradiation[J].Int J Radiat Oncol Biol Phys,2003,57(3):875-890.DOI:10.1016/S0360-3016(03)00743-0 [20] Gomez DR,Tucker S,Martel MK,et al. Predictors of high-grade esophagitis after Three-definitive conformal therapy,intensity-modulated radiation therapy,or proton beam therapy for non-small cell lung cancer[J].Int J Radiat Oncol Biol Phys,2012,84(4):1010-1016.DOI:10.1016/j.ijrobp.2012.01.071 [21] Hirota S,Tsujino K,Endo M,et al. Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy[J].Int J Radiat Oncol Biol Phys,2001,51(2):291-295.DOI:10.1016/S0360-3016(01)01648-0 [22] Patel AB,Edelman MJ,Kwok Y,et al. Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery[J].Int J Radiat Oncol Biol Phys,2004,60(4):1106-1112.DOI:10.1016/j.ijrobp.2004.04.051 [23] Zhang ZC,Xu J,Li BS,et al. Clinical and dosimetric risk factors of acute esophagitis in patients treated with 3-dimensional conformal radiotherapy for non-small-cell lung cancer[J].Am J Clin Oncol,2010,33(3):271-275.DOI:10.1097/COC.0b013e3181a879e0 [24] Langer CJ,Movsas B,Hudes R,et al. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable,locally advanced non-small cell lung carcinoma:report of Fox Chase Cancer center Study94-001[J].Semin Oncol,1997,24(4 Suppl 12):S12-89-S12-95
2016, Vol. 25 
